On multivariable analysis, baseline PSA level, pN1, and high nYAP intensity in residual cancer cells were independent prognostic factors for BCR in patients with PCa treated with CHT, followed by RP (hazard ratio [HR] = 1.03; 95% confidence interval [CI], 1.01–1.05, p = 0.010; HR = 3.94; 95% CI, 1.06–14.62, p = 0.040; HR = 3.32; 95% CI, 1.32–8.37, p = 0.011; respectively, Table 2). The gene discussed is BCR; the disease is cancer.